This announcement is made by Laekna, Inc. (the ‘‘Company’’, together with its subsidiaries, the ‘‘Group’’) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board (the ‘‘Board’’) of directors of the Company (the ‘‘Directors’’) is pleased to announce that on 9 June 2026, the Group and Vasque Bio, Inc. (‘‘Vasque Bio’’) have entered into an exclusive licensing agreement (the ‘‘License Agreement’’).

PRINCIPAL TERMS OF THE LICENSE AGREEMENT

Subject to terms and conditions of the License Agreement, Vasque Bio is granted, among other rights, an exclusive, worldwide license (excluding Chinese Mainland, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan) (the ‘‘Licensed Territory’’) to develop, manufacture, commercialize and otherwise exploit LAE118 (an internally discovered Novel PI3KαPan-Mutant Selective Inhibitor). In return, the Group is entitled to receive a non-refundable and non-creditable upfront cash payment of USD10 million and the right to acquire, for no additional consideration, up to high teen percentage of Vasque Bio’s outstanding common stock or cash payments in lieu of such common stock. Under the License Agreement, the Group is also eligible to receive development and sales milestone payments up to USD517 million in total, as well as tiered royalty payments ranging from single-digit to double-digit percentages on future net sales of LAE118 in the Licensed Territory. In the event of a qualifying strategic partnering or acquisition transaction meeting certain conditions pertaining to the use of LAE118 entered by Vasque Bio, the Group shall be entitled to receive additional payments of up to 50% of such strategic transaction value.

REASONS FOR AND BENEFITS OF THE LICENSE AGREEMENT

The Board believes that entering into the License Agreement is in the best interests of the Company and its shareholders as a whole. Vasque Bio focuses primarily on the development of therapeutics for rare diseases, while the Group focuses on developing LAE118 for oncology outside the Licensed Territory. The Group can leverage this opportunity to accelerate the global development and commercialization of LAE118 in the Licensed Territory into a broader range of indications and expedite its downstream value creation (e.g. licensing, partnership, or M&A exit). The upfront and milestone payments will strengthen the Group’s financial position to support its future development. The right to receive Vasque Bio’s outstanding common stock also enables the Group to retain economic exposure to the future upside of LAE118. Currently, the Group is in active discussions with multiple potential partners and intends to pursue strategic partnerships to accelerate clinical development and commercialization of its drug candidate assets. Maintaining solid financial positions allows us to be selective in evaluating potential partnership structures that align the interests of all parties to maximize the potential of our assets.

To the best knowledge, information and belief of the Company, as of the date of this announcement, Vasque Bio is independent of, and not connected with, the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the ‘‘Listing Rules’’)). The transactions contemplated under the License Agreement do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

ABOUT LAE118

LAE118 is an internally discovered novel PI3Kαpan-mutant selective inhibitor. As of the date of this announcement, the Group has obtained Investigational New Drug approval from the U.S. Food and Drug Administration (the ‘‘FDA’’) and the Centre for Drug Evaluation of the National Medical Products Administration of China (the ‘‘CDE’’) for LAE118 and is actively advancing this drug candidate to clinical studies as novel therapies for PIK3CAmutant solid tumors.

ABOUT VASQUE BIO

Vasque Bio is a U.S.-based, clinical-stage biotechnology company dedicated to the development of therapeutics to transform the standard of care for people living with serious, life-altering rare diseases. Vasque Bio is supported by a renowned consortium of top-tier life science investors, including The Column Group (‘‘TCG’’) and F-Prime.

RISK WARNING

LAE118 MAY ULTIMATELY NOT BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY’S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By Order of the Board

Laekna, Inc.

Dr. LU Chris Xiangyang

Chairman

Hong Kong, 9 June, 2026

As of the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.

–  End –

Contact Us

IR  ir@laekna.com

Corporate and Business Development  BD@laekna.com

About Laekna

HKEK Stock Code: 2105.HK

Patient needs in major disease areas—such as metabolic diseases, oncology, and liver fibrosis—remain the driving force behind our mission. Laekna, a science-driven biotechnology company, is committed to bringing novel therapeutics to patients around the world.

Leveraging our tremendous experience and extensive know-how in disease biology, we have built a pipeline of over 20 internally discovered innovative drug candidates with proprietary intellectual property rights. We keep expanding our global reach through strategic partnerships, fostering collaborative success across regions.

In oncology, we have completed subject enrollment for the Phase III clinical trial of LAE002 (afuresertib, an AKT inhibitor) for breast cancer (AFFIRM-205). We plan to submit NDA to the CDE in 2026, which will mark Laekna’s pivotal transition from clinical development to commercialization. Laekna has entered into an exclusive licensing agreement with Qilu Pharma to further accelerate the delivery of this novel therapeutic to patients across China.

In metabolic diseases, building on our deep expertise and extensive knowhow in the ActRII pathway, we have established a globally competitive, differentiated portfolio comprising LAE102, LAE103, and LAE123. We are rapidly advancing the clinical development of LAE102 in both China and the United States. In the U.S., Laekna has successfully completed the Phase I SAD study, in collaboration with Eli Lilly, to accelerate the global development of this high-quality weight management therapy.

From our laboratory in Zhangjiang Pharma Valley in Shanghai, to clinical trials conducted across China, the U.S., and Australia, our footprint spans the globe. Looking ahead, Laekna will continue to collaborate with international partners to accelerate delivery of novel therapeutics to patients worldwide.

For more information, please visit: https://www.laekna.com/  or https://www.linkedin.com/company/74110713/

Forward-Looking Statements

This press release may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on Laekna’s current beliefs, assumptions and expectations, commonly identified by words such as "would", "may", "expects", "believes", "plans", "intends", "projects" and other terms with similar meaning. Although we believe that our predictions are reasonable, future events are inherently uncertain and our actual future results or performance may be materially different from what we expect. Accordingly, you are strongly cautioned that reliance on any forward-looking statements is subject to significant known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.